Blog

ASCO’s new living guideline update for Stage IV NSCLC with Driver Alterations

Lung Cancer

Mar 3, 2025, 10:24

ASCO’s new living guideline update for Stage IV NSCLC with Driver Alterations

American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:

“The American Society of Clinical Oncology’s (ASCO) new living guideline update, Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, is now available.

Updated recommendations include that clinicians can now consider osimertinib combined with platinum-based chemotherapy or the combination of amivantamab and lazertinib as potential treatment options.

Read more.”

ASCO's new living guideline update for Stage IV NSCLC with Driver Alterations

American Society of Clinical Oncology Amivantamab ASCO cancer chemotherapy fight against cancer Global fight against cancer lazertinib non small cell lung cancer NSCLC OncoDaily Oncology osimertinib

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience